GSK GlaxoSmithKline plc (ADR)

39.31
0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial commenced 4Q 2016.
Daprodustat - ASCEND-ND
Anemia
Phase 3 trial commenced August 2016.
Dolutegravir + lamivudine (GEMINI 2)
HIV
Phase 2b data due 2H 2017.
GSK 165
Rheumatoid arthritis
sBLA filing announced March 15, 2017.
Fluarix Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
Phase 3 data due 2017.
Nucala
Chronic obstructive pulmonary disease (COPD)
Regulatory filing due 2017.
Mepolizumab
Eosinophilic lung disease (EGPA)
Phase 3 trial met primary endpoint - December 2016. Filing to be submitted 2017.
Dolutegravir + rilpivirine:
HIV
Phase 3 trial commenced August 2016.
Dolutegravir + lamivudine (GEMINI 1)
HIV
Phase 3 study completion due 2018.
Closed Triple
Asthma
Phase 3 trial commenced 4Q 2016.
Daprodustat - ASCEND-D
Anemia
Phase 3 commenced December 2016.
Cabotegravir long-acting
HIV
Phase 2b trial to be initiated 2017.
Inhaled PI3Kδ inhibitor
Chronic obstructive pulmonary disease (COPD)
Phase 2b data due 2H 2017.
GSK 166
Rheumatoid arthritis
Phase 2 data due 2H 2017.
GSK 165
Osteoarthritis
Phase 2b trial to be initiated May 2017.
Danirixin
Chronic obstructive pulmonary disease (COPD)
BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017.
Sirukumab
Rheumatoid arthritis
BLA filing announced October 24, 2016. PDUFA estimate October 24, 2017.
Shingrix
Shingles
Filing announced Novermber 21, 2016. PDUFA estimate September 21, 2017.
FF/UMEC/VI
Chronic obstructive pulmonary disease (COPD)
BLA filing announced September 23, 2016. PDUFA estimate July 23, 2017.
Benlysta (belimumab) - subcutaneous
Systemic lupus erythematosus (SLE)

Latest News

  1. 3 Dividend Stocks That Retirees Should Avoid
  2. Barclays -- Mired In Mud (Again) -- Should Dump Its CEO
  3. Analyst Estimates for Novartis’s 1Q17 Earnings
  4. What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?
  5. 4 Stocks Are Showing Red Flags -- Here's When to Sell
  6. $3M award in suit against drug company over man's suicide
  7. Teva's new asthma inhaler poses first competition for GSK's Advair
  8. Here's Why Innoviva Inc. Lost 10% Today
  9. GSK must pay $3 million in generic Paxil suicide lawsuit: U.S. jury
  10. As Price Falls, Vetr Upgrades GlaxoSmithKline To Buy
  11. Innoviva director vote drama hands last-minute loss to Sarissa
  12. ZappRX gets $25 million from Qiming US to expand into the U.S. drug prescription market
  13. Activist Sarissa says Innoviva backed out of proxy settlement deal
  14. There Have Been Few Losers Since The Brexit Vote, But It's About To Get Ugly
  15. ($$) Science looks to nucleic acids to create right genetic vaccine recipe
  16. Blog Coverage Bristol-Myers and Nordic Announce an Agreement for Development of Fibrosis Biomarker Technology
  17. OncoMed's lung cancer drug fails mid-stage study, shares tumble
  18. Innoviva to review costs, executive pay following Sarissa pressure
  19. This Survey's Bad News Could Be Good News for Inovio Pharmaceuticals, Inc.
  20. Hearing loss biotech Frequency Therapeutics dials up $32M round